MIDDLE EAST AND AFRICA ALZHEIMER’S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET 2022-2028

Lifesciences | Diagnostic & Biotechnology

MIDDLE EAST AND AFRICA ALZHEIMER’S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET 2022-2028

Market by Therapeutics, Diagnostics, and Country Outlook | Forecast 2022-2028

Request Free Sample

Request Custom Report

Request Custom Report

Enquire before buying

Enquire Before Buying

A report by Triton Market Research shows that the market for Alzheimer’s disease therapeutics and diagnostics in the Middle East and Africa will grow with a CAGR of 5.81% in the forecast duration 2022-2028.


Report scope can be customized per your requirements. Request For Customization 

The countries scrutinized in this market include:

•         Turkey

•         South Africa

•         The United Arab Emirates

•         Saudi Arabia

•         Rest of Middle East & Africa

Several countries in the Middle East are preferred destinations for medical tourism, which has led to increased investments and attracted the attention of leading market players to the region, especially the UAE and Saudi Arabia. However, in the African nations, Alzheimer’s does not receive much attention due to the lack of awareness, infrastructure, and skilled professionals in this field. Overall, the growing elderly population is expected to enhance the need for therapeutics and diagnostics for Alzheimer’s disease in the region.

Latest statistics indicate that close to 400,000 people in Turkey are affected by AD. The establishment of institutions like the Turkish Alzheimer Society and Turkish Alzheimer Foundation, which are working to raise the disease’s awareness and improve the treatment and care offered to Alzheimer’s disease patients, is expected to foster the market’s growth.

In the United Arab Emirates, various government-affiliated institutions, as well as NGOs, are initiating programs to increase awareness regarding Alzheimer’s disease, which is expected to positively influence the demand for AD therapeutics and diagnostics. For instance, the Ministry of Health and Prevention, in September 2020, organized several activities for World Alzheimer’s Day to raise public awareness about the importance of early disease diagnosis and treatment.

The increased healthcare spending has resulted in the higher adoption of advanced diagnostic methods for AD treatment. Positron emission tomography (PET) is one such technique, which uses a computer, a camera, and small amounts of radioactive materials known as radiotracers to evaluate organ and tissue malfunctions in the diagnosis process. A PET scan detects and records a significantly larger percentage of emitted rays. Additionally, PET scanners facilitate easy diagnosis, owing to numerous advantages, which is expected to increase the demand for positron emission tomography.

The report assesses the market according to diagnostics and therapeutics. Here, the diagnostics segment comprises positron emission tomography, lumbar puncture test, blood test, computed tomography, electroencephalography, magnetic resonance imaging, and other diagnostics.

Some of the notable companies in the Alzheimer’s disease therapeutics and diagnostics market are Johnson and Johnson, Lupin Limited, Biogen Inc, Pfizer Inc, F. Hoffmann-La Roche AG, Novartis AG, Allergan Plc (acquired by Abbvie), Amarantus Bioscience Holdings Inc, and GE Healthcare.

Teva Pharmaceutical Industries Ltd is a leading company with a primary focus on generic drugs, active pharmaceutical ingredients (API), and proprietary pharmaceuticals to a certain extent. It is the world’s largest generic medicine manufacturer. The company manufactures solid dosage forms, semi-solids, liquids, sterile injectables, transdermal patches, inhalers, and other medical devices. Teva Pharmaceutical offers Donepezil and Quetiapine for Alzheimer’s treatment. Founded in 1935, the company is headquartered in Petach Tikva, Israel.

 

Key deliverables of the report:

·       Market CAGR during the forecasting years 2022-2028

·       Detailed data highlighting key insights, industry components, and market strategies

·       Comprehensive information and estimation of the Alzheimer’s disease therapeutics and diagnostics market revenue growth in the Middle East and Africa and its influence on the parent market

·       In-depth study of forthcoming trends in consumer behavioral patterns

·       A meticulous analysis of the competitive landscape, vendor scorecard, and Porter’s Five Forces Model

·       A wide-ranging study of factors that will challenge the Middle East and Africa Alzheimer’s disease therapeutics and diagnostics market’s growth during the upcoming years

Want to get specific insights? Our team of analysts can customize this report based on your preferences. Connect with us here

Related Reports

ASIA PACIFIC AESTHETIC LASER MARKET 2019-2027
Lifesciences

ASIA PACIFIC AESTHETIC LASER MARKET 2019-2027

Market By Type, Application, E ..

VIEW REPORT
ASIA PACIFIC BIOCHIPS MARKET 2019-2027
Lifesciences

ASIA PACIFIC BIOCHIPS MARKET 2019-2027

Market By Type, Substrate Mate ..

VIEW REPORT
ASIA PACIFIC BIOPSY DEVICE MARKET 2019-2027
Lifesciences

ASIA PACIFIC BIOPSY DEVICE MARKET 2019-2027

Market By Device Type, Therape ..

VIEW REPORT
ASIA PACIFIC DNA VACCINES MARKET 2019-2027
Lifesciences

ASIA PACIFIC DNA VACCINES MARKET 2019-2027

Market By Type, Application, T ..

VIEW REPORT
ASIA-PACIFIC 3D CELL CULTURE MARKET 2019-2027
Lifesciences

ASIA-PACIFIC 3D CELL CULTURE MARKET 2019-2027

Market By Technology, Applicat ..

VIEW REPORT
ASIA-PACIFIC AIRWAY CLEARANCE SYSTEM MARKET 2019-2028
Lifesciences

ASIA-PACIFIC AIRWAY CLEARANCE SYSTEM MARKET 2019-2028

Market By Application, Type, E ..

VIEW REPORT

Table of Content

1. MIDDLE EAST AND AFRICA ALZHEIMER’S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET – SUMMARY

2. INDUSTRY OUTLOOK

2.1. TIMELINE OF ALZHEIMER’S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET

2.2. PHASES AND STERNNESS OF ALZHEIMER’S DISEASE

2.3. KEY INSIGHTS

2.3.1. USAGE OF COMPUTED TOMOGRAPHY FOR THE DIAGNOSIS OF ALZHEIMER’S DISEASE

2.3.2. R&D INVESTMENTS IN BIOMARKERS FOR EARLY DETECTION OF DEMENTIA

2.3.3. DEMAND FOR PERSONALIZED MEDICINES 

2.4. IMPACT OF COVID-19 ON THE ALZHEIMER’S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET

2.5. PORTER’S FIVE FORCES ANALYSIS

2.6. MARKET ATTRACTIVENESS MATRIX

2.7. VENDOR SCORECARD

2.8. INDUSTRY COMPONENTS

2.8.1. RESEARCH & DEVELOPMENT (R & D)

2.8.2. RAW MATERIALS

2.8.3. MANUFACTURING

2.8.4. DISTRIBUTORS/WHOLESALERS/RETAILERS

2.8.5. END-USER

2.9. KEY IMPACT ANALYSIS

2.9.1. EFFECTIVENESS

2.9.2. PRICE

2.9.3. SAFETY

2.10. KEY MARKET STRATEGIES

2.10.1. ACQUISITIONS

2.10.2. PRODUCT LAUNCHES

2.10.3. CONTRACTS & AGREEMENTS

2.10.4. INVESTMENTS & EXPANSIONS

2.11. MARKET DRIVERS

2.11.1. PREVALENCE OF ALZHEIMER’S DISEASE

2.11.2. RISE IN THE ELDERLY POPULATION

2.12. MARKET CHALLENGES

2.12.1. FAILURE OF LATE-STAGE DRUGS

2.12.2. STRINGENT GOVERNMENT REGULATIONS

2.13. MARKET OPPORTUNITIES

2.13.1. EMERGENCE OF NEW DIAGNOSTIC TECHNOLOGIES

2.13.2. GROWING NUMBER OF PIPELINE DRUGS

3. MIDDLE EAST AND AFRICA ALZHEIMER’S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET – BY THERAPEUTICS

3.1. BY DRUG TYPE

3.1.1. MARKETED DRUGS

3.1.2. PIPELINE DRUGS

3.2. BY DISEASE STAGE

3.2.1. LATE STAGE: SEVERE AD

3.2.2. EARLY/MIDDLE STAGE: MILD TO MODERATE AD

3.2.3. PRODROMAL STAGE

3.3. BY GENERIC & BRANDED

3.3.1. BRANDED

3.3.2. GENERIC

4. MIDDLE EAST AND AFRICA ALZHEIMER’S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET – BY DIAGNOSTICS

4.1. LUMBAR PUNCTURE TEST

4.2. POSITRON EMISSION TOMOGRAPHY

4.3. ELECTROENCEPHALOGRAPHY

4.4. MAGNETIC RESONANCE IMAGING

4.5. COMPUTED TOMOGRAPHY

4.6. BLOOD TEST

4.7. OTHER DIAGNOSTICS

5. MIDDLE EAST AND AFRICA ALZHEIMER’S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET – COUNTRY OUTLOOK

5.1. UNITED ARAB EMIRATES

5.2. TURKEY

5.3. SAUDI ARABIA

5.4. SOUTH AFRICA

5.5. REST OF MIDDLE EAST & AFRICA

6. COMPETITIVE LANDSCAPE

6.1. BAXTER INTERNATIONAL INC

6.2. F. HOFFMANN-LA ROCHE AG

6.3. ALLERGAN PLC (ACQUIRED BY ABBVIE)

6.4. NOVARTIS AG

6.5. PFIZER INC

6.6. SIEMENS HEALTHINEERS AG

6.7. AMARANTUS BIOSCIENCE HOLDINGS INC

6.8. EISAI CO LTD

6.9. ELI LILLY & COMPANY

6.10. LUPIN LIMITED

6.11. MERCK AND CO

6.12. BIOGEN INC

6.13. COGNOPTIX INC

6.14. GE HEALTHCARE

6.15. JOHNSON AND JOHNSON

6.16. SUN PHARMACEUTICALS INDUSTRIES LTD

6.17. TEVA PHARMACEUTICAL INDUSTRIES LTD

6.18. ZYDUS CADILA

7. METHODOLOGY & SCOPE

7.1. RESEARCH SCOPE

7.2. SOURCES OF DATA

7.3. RESEARCH METHODOLOGY

List of Tables

TABLE 1: MIDDLE EAST AND AFRICA ALZHEIMER’S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET, COUNTRY OUTLOOK, 2022-2028 (IN $ MILLION)

TABLE 2: MARKET ATTRACTIVENESS MATRIX      

TABLE 3: VENDOR SCORECARD       

TABLE 4: KEY STRATEGIC DEVELOPMENTS

TABLE 5: MIDDLE EAST AND AFRICA ALZHEIMER’S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET, BY THERAPEUTICS, 2022-2028 (IN $ MILLION)        

TABLE 6: MIDDLE EAST AND AFRICA ALZHEIMER’S DISEASE THERAPEUTICS MARKET, BY DRUG TYPE, 2022-2028 (IN $ MILLION)

TABLE 7: MIDDLE EAST AND AFRICA ALZHEIMER’S DISEASE THERAPEUTICS MARKET, BY DISEASE STAGE, 2022-2028 (IN $ MILLION)         

TABLE 8: MIDDLE EAST AND AFRICA ALZHEIMER’S DISEASE THERAPEUTICS MARKET, BY GENERIC & BRANDED, 2022-2028 (IN $ MILLION)    

TABLE 9: MIDDLE EAST AND AFRICA ALZHEIMER’S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET, BY DIAGNOSTICS, 2022-2028 (IN $ MILLION)        

TABLE 10: MIDDLE EAST AND AFRICA ALZHEIMER’S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET, COUNTRY OUTLOOK, 2022-2028 (IN $ MILLION)

List of Figures

FIGURE 1: PORTER’S FIVE FORCES ANALYSIS

FIGURE 2: KEY IMPACT ANALYSIS

FIGURE 3: TIMELINE OF ALZHEIMER’S DISEASE THERAPEUTICS AND DIAGNOSTICS

FIGURE 4: INDUSTRY COMPONENTS          

FIGURE 5: MIDDLE EAST AND AFRICA ALZHEIMER’S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET, BY THERAPEUTICS, 2021 & 2028 (IN %)

FIGURE 6: MIDDLE EAST AND AFRICA ALZHEIMER’S DISEASE THERAPEUTICS MARKET, BY DRUG TYPE, 2021 & 2028 (IN %)

FIGURE 7: MIDDLE EAST AND AFRICA ALZHEIMER’S DISEASE THERAPEUTICS MARKET, BY MARKETED DRUGS, 2022-2028 (IN $ MILLION)

FIGURE 8: MIDDLE EAST AND AFRICA ALZHEIMER’S DISEASE THERAPEUTICS MARKET, BY PIPELINE DRUGS, 2022-2028 (IN $ MILLION)

FIGURE 9: MIDDLE EAST AND AFRICA ALZHEIMER’S DISEASE THERAPEUTICS MARKET, BY DISEASE STAGE, 2021 & 2028 (IN %)

FIGURE 10: MIDDLE EAST AND AFRICA ALZHEIMER’S DISEASE THERAPEUTICS MARKET, BY LATE STAGE: SEVERE AD, 2022-2028 (IN $ MILLION)

FIGURE 11: MIDDLE EAST AND AFRICA ALZHEIMER’S DISEASE THERAPEUTICS MARKET, BY EARLY/MIDDLE STAGE: MILD TO MODERATE AD, 2022-2028 (IN $ MILLION)

FIGURE 12: MIDDLE EAST AND AFRICA ALZHEIMER’S DISEASE THERAPEUTICS MARKET, BY PRODROMAL STAGE, 2022-2028 (IN $ MILLION)

FIGURE 13: MIDDLE EAST AND AFRICA ALZHEIMER’S DISEASE THERAPEUTICS MARKET, BY GENERIC & BRANDED, 2021 & 2028 (IN %)

FIGURE 14: MIDDLE EAST AND AFRICA ALZHEIMER’S DISEASE THERAPEUTICS MARKET, BY BRANDED, 2022-2028 (IN $ MILLION)

FIGURE 15: MIDDLE EAST AND AFRICA ALZHEIMER’S DISEASE THERAPEUTICS MARKET, BY GENERIC, 2022-2028 (IN $ MILLION)

FIGURE 16: MIDDLE EAST AND AFRICA ALZHEIMER’S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET, BY DIAGNOSTICS, 2021 & 2028 (IN %)

FIGURE 17: MIDDLE EAST AND AFRICA ALZHEIMER’S DISEASE DIAGNOSTICS MARKET, BY LUMBAR PUNCTURE TEST, 2022-2028 (IN $ MILLION)

FIGURE 18: MIDDLE EAST AND AFRICA ALZHEIMER’S DISEASE DIAGNOSTICS MARKET, BY POSITRON EMISSION TOMOGRAPHY, 2022-2028 (IN $ MILLION)

FIGURE 19: MIDDLE EAST AND AFRICA ALZHEIMER’S DISEASE DIAGNOSTICS MARKET, BY ELECTROENCEPHALOGRAPHY, 2022-2028 (IN $ MILLION)

FIGURE 20: MIDDLE EAST AND AFRICA ALZHEIMER’S DISEASE DIAGNOSTICS MARKET, BY MAGNETIC RESONANCE IMAGING, 2022-2028 (IN $ MILLION)

FIGURE 21: MIDDLE EAST AND AFRICA ALZHEIMER’S DISEASE DIAGNOSTICS MARKET, BY COMPUTED TOMOGRAPHY, 2022-2028 (IN $ MILLION)

FIGURE 22: MIDDLE EAST AND AFRICA ALZHEIMER’S DISEASE DIAGNOSTICS MARKET, BY BLOOD TEST, 2022-2028 (IN $ MILLION)

FIGURE 23: MIDDLE EAST AND AFRICA ALZHEIMER’S DISEASE DIAGNOSTICS MARKET, BY OTHER DIAGNOSTICS, 2022-2028 (IN $ MILLION)

FIGURE 24: MIDDLE EAST AND AFRICA ALZHEIMER’S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET, COUNTRY OUTLOOK, 2021 & 2028 (IN %)        

FIGURE 25: UNITED ARAB EMIRATES ALZHEIMER’S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET 2022-2028 (IN $ MILLION)         

FIGURE 26: SAUDI ARABIA ALZHEIMER’S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET 2022-2028 (IN $ MILLION) 

FIGURE 27: TURKEY ALZHEIMER’S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET 2022-2028 (IN $ MILLION) 

FIGURE 28: SOUTH AFRICA ALZHEIMER’S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET 2022-2028 (IN $ MILLION) 

FIGURE 29: REST OF MIDDLE EAST & AFRICA ALZHEIMER’S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET 2022-2028 (IN $ MILLION)

Purchase Options

  • Licence Type
  • Price
  • User/Sharing
  • Printing
  • Delivery Formats
  • Free customization (Pre-sale)
  • Analyst hour support (Post Sale)
  • Customized notification for newly published report
  • Free report on update (within 180 days)

Single User PDF

$1,500.00

  • User/Sharing
  • Restricted to one authorized user
  • Printing
  • Not printable
  • Delivery Formats
  • Pdf
  • Free customization (Pre-sale)
  • 10% Free customization
  • Analyst hour support (Post Sale)
  • 3 hours
  • Customized notification (newly published)
  • Free report on update (within 180 days)

Enterprise Online/PDF

$2,200.00

  • User/Sharing
  • Unlimited
  • Printing
  • Unlimited
  • Delivery Formats
  • Pdf and market estimation excel
  • Free customization (Pre-sale)
  • 20% Free customization
  • Analyst hour support (Post Sale)
  • 8 hour
  • Customized notification (newly published)
  • Free report on update (within 180 days)

Request free Sample

SUBMIT REQUEST
Request Custom Report

Request Custom Report

Enquire before buying

Enquire Before Buying

;